Ulcerative Colitis

Resource Center

Commentary

News

Ulcerative Colitis

FDA Approves Option for Pediatric Ulcerative Colitis

02/25/2021

The FDA has approved Humira (Adalimumab) for the treatment of moderately to severly active ulcerative colitis (UC) in pediatric patients aged 5 years or older.

02/25/2021

Ulcerative Colitis

AGA Releases Guideline for Management of Moderate to Severe UC

01/14/2020

The guideline authors developed more than 10 recommendations with the goal of promoting high-quality, high-value, evidence-based care for adult patients with moderate to severe ulcerative colitis.

01/14/2020

Ulcerative Colitis

FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis

12/12/2019

XELJANZ XR provides adult patients living with moderately to severely active UC the first and only once-daily JAK inhibitor for managing their disease.

12/12/2019

Ulcerative Colitis

FDA Issues Safety Alert for a JAK Inhibitor

07/26/2019

The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.

07/26/2019

Ulcerative Colitis

Therapeutic Options in Ulcerative Colitis: Choosing Initial Therapy Is Key

07/20/2019

At the Advances in Inflammatory Bowel Diseases Regional in Chicago, Illinois, David T. Rubin, MD, from The University of Chicago, highlights the recent and emerging therapies in ulcerative colitis, as well...

07/20/2019

June 2022

Current Issue

June 2022

Volume 62

Issue 6